Vical Incorporated (NASDAQ: VICL ) Q2 2014 Results Earnings Conference Call July 31, 2014 12 ..... Presentation Operator Good day and welcome ladies and gentlemen to the Vical Incorporated Financial Results Conference Call. At this time, I would
Vical (NASDAQ: VICL ): Q2 EPS of -$0.05 in-line. Revenue of $4.5M (+208.2% Y/Y) beats by $2.6M . Press Release Post your comment!
PNW , PPL , PRFT , PWR , Q , RFP , RYL , SBH , SC , SCG , SFY , SHOO , SNAK , SNMX , STC , STRA , STRZA , SUP , SWC , TE , TEVA , TKR , TRP , TWC , UAN , UPL , USAK , VG , VICL , VNTV , VRX , WLT , WWE , XEL , XOM , XRAY Post your comment!
We are no longer providing equity research on Vical VICL . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
Vical VICL has reported positive preclinical results from its H1N1 swine flu vaccine, but we will maintain our fair value estimate until
Vical VICL announced strong first-quarter results and a collaboration with the U.S. Navy on swine flu, or H1N1 influenza, Thursday
We are maintaining our fair value estimate for Vical VICL as its development progress remains on track. The firm burned through $7 million in cash during the fourth quarter and ended
On Friday, Vical VICL announced plans to restructure its operations. While this will reduce its near-term cash burn, we are holding firm to our fair
After running more valuation scenarios, we're returning our fair value uncertainty rating for Vical VICL to very high from extreme. Our fair value estimate remains unchanged. Our current valuation depends on Vical obtaining about
We're raising our fair value uncertainty rating for Vical VICL to extreme from very high to account for the stock market's recent volatility. Until we have a better sense of the firm's